BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Endothelial cell
,
DNA fingerprint
,
Prozac
,
rs6983267
,
CXCL2
,
Coagulation
,
HIV infection
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
Pr(III
Summary
General Info
Curated Studies
Most Correlated Studies
There were no matches for Pr(III
Explore Curated Studies Results
Literature
Most Relevant Literature
Oxoaporphine Pr(III) complex inhibits hepatocellular carcinoma progression and metastasis by disrupt…
Delicate, a study of the structural changes in ten-coordinated La(III), Ce(III), Pr(III), Nd(III), S…
Extraction and Back-Extraction Behaviors of La(III), Ce(III), Pr(III), and Nd(III) Single Rare Earth…
Pr(III) luminescence enhancement by chelation in solution and in sol-gel glass.
Preparation of new fluorophore lanthanide complexes-Cloisite nanohybrids using the tricationic Pr(II…
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of Six Months Treatm…
Phase 2a Study to Evaluate PRS-080 in Anemic Chronic Kidney Disease Patients
Efficacy and Safety of Danoprevir/r + PR 12week Triple Therapy in Treatment Naive Non-Cirrhotic G1 C…
Phase Ib Study to Evaluate PRS-080 in Anemic Chronic Kidney Disease Patients
Efficacy and Safety of Lanreotide AutogelĀ® 60, 90 or 120 mg With Lanreotide 40 mg Prolonged Release …
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ